CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Palobiofarma is developing PBF-680, a unique therapy targeting adenosine receptors to treat chronic obstructive pulmonary disease (COPD). This first-in-class drug aims to reduce symptoms and inflammation in patients, addressing a significant unmet medical need.
Palobiofarma is a Spanish biotech company with the ambition to develop new treatments for cancer and autoimmune diseases based on adenosine receptor modulation.
Our compound PBF-680 is a first-in-class therapy with disease modifying effects in respiratory diseases like COPD.
Over 65M patients suffer from COPD, yet there are no approved therapies that target disease progression. PBF-680 is a unique molecule designed to specifically antagonise the Adenosine 1 Receptor (A1R). it has shown to…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
